A Simon Thompson double bill, Chris Dillow on growth stocks & Consort offers an alternative

In a double bill of columns today, Simon Thompson has been running his slide rule over a specialist provider of finance to small- and medium-sized enterprises that has posted eye-catching annual results, but is priced below book value and on a single digit earnings multiple; and a fund manager of alternative asset classes that has reached a major inflexion point and is now set to deliver highly profitable growth and a progressive dividend, too. Simon has published a total of 10 columns since the start of last week, all of which can be viewed on his homepage, and his latest small-cap equity report for Alpha subscribers.

Are growth stocks now overvalued? Chris Dillow takes a look at some big risks facing growth stocks. But are valuations everything? Click here to find out.

Consort Medical has entered the addiction treatment market, partnering with Opiant Pharmaceuticals. In this week's News Spotlight Megan Boxall takes a look at how UK investors now have an alternative way to access a very attractive industry. 

Related topics

Subscribe today

Full access for just £3.37 a week:

• Tips and recommendations - to beat the market 
• Portfolio clinic & Mr Bearbull - build a well-planned portfolio 
• Expert tools - track and manage investments effortlessly
• Plus free delivery to your home or office

Subscribe Now